Objective: One year observation and evaluation of the VNS (vagus nerve stimulation) efficacy and safety for patients with treatment resistant depression in Polish conditions.
Vagus nerve stimulation (VNS) was the first neuromodulation device approved for treatment of epilepsy. In more than 20 years of study, VNS has consistently demonstrated efficacy in treating epilepsy.
Cefaly Technology, the creators of the first FDA-approved transcutaneous electrical nerve stimulation device, specifically authorized for use prior to the...
LivaNova PLC a market-leading medical technology and innovation company, announced its Vagus Nerve Stimulation Therapy (VNS Therapy) System, Symmetry, earned CE Mark approval for Difficult-to-Treat Depression (DTD).
A new study finds that Cefaly, the first FDA-approved transcutaneous electrical nerve stimulation device specifically authorized for use prior to...
LivaNova PLC announced it received CE Mark for its Vagus Nerve Stimulation Therapy System comprised of the SenTiva generator and...
LivaNova PLC announced it received CE Mark for its Vagus Nerve Stimulation Therapy (�VNS Therapy�) System comprised of the SenTiva...
SetPoint Medical, presented positive results from an ongoing study modulating the inflammatory reflex to treat Crohn's Disease (CD), a debilitating...
This study aimed to examine the most reliable evidence on the relationship between early menopause and the risk of heart failure and atrial fibrillation.
Sorin S.p.A., a global medical device company and a leader in the treatment of cardiovascular diseases, and Cyberonics, Inc.,a medical...